MTOR and kidney cancer: Although LPA is elevated (along with autotaxin (ATX)) in kidney cancers [13–15] and can promote malignancy of patient-derived tumor cells [40], the role of this mitogenic lipid in chemotherapeutic resistance with the mTOR inhibitor, TEMS, has not yet been explored.